Intravenous azlocillin kinetics in patients on long‐term hemodialysis | Zendy

Aletta John M | Zendy; Francke Elliot F | Zendy; Neu Harold C | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Intravenous azlocillin kinetics in patients on long‐term hemodialysis

Author(s) -

Aletta John M,

Francke Elliot F,

Neu Harold C

Publication year - 1980

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.1980.80

Subject(s) - azlocillin , hemodialysis , dialysis , medicine , half life , penicillin , pharmacokinetics , clearance , chemistry , urology , antibiotics , biochemistry , genetics , bacteria , pseudomonas aeruginosa , biology , piperacillin

The kinetics of the antipseudomonas penicillin, azlocillin, was studied after intravenous injection in 9 patients with creatinine clearance under 7 ml/min. All were on long‐term hemodialysis; 3 were also studied during a dialysis‐free period. Kinetic parameters were derived using a 2‐compartment open model. The mean serum azlocillin half‐life (t½) was 1.93 hr in patients on dialysis and approximately 5 hr off dialysis. Thirty percent of the dose was recovered in the dialysate during a 4‐hr period. An approach to the use of azlocillin in patients undergoing dialysis is presented. Clinical Pharmacology and Therapeutics (1980) 27, 563–566; doi: 10.1038/clpt.1980.80

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research